◎ Sugi Atlas

Atlas / Drug / Ivermectin

Ivermectin

drug
On this page

Also known as AcarexxBimectinBovinetCardomecCardotek 30CD-5024CD5024CevamecDihydroavermectin b1aEquimecEqvalanHeartgardHyvermectinHeartguardIvectinIvermectin b1aIvermectin component of b1aIvermectinaIvermectine

Summary

Ivermectin (CHEMBL6067487) is an approved unknown (ATC D11AX22) targeting CHRNA7, P2RX4, and P2RX7; indicated across 23 conditions including rosacea and onchocerciasis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Unknown
  • ATC class: D11AX22 (+1 more)
  • Targets: 3 (CHRNA7, P2RX4, P2RX7)
  • Indications: 23 conditions
  • Clinical trials: 165

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL6067487
NameIvermectin
TypeUnknown
Max phase4
ATCD11AX22, P02CF01

Also known as: Acarexx, Bimectin, Bovinet, Cardomec, Cardotek 30, CD-5024, CD5024, Cevamec, Dihydroavermectin b1a, Equimec, Eqvalan, Heartgard

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
Glycine Receptor (All subtypes)Irreversible agonist6.4
CHRNA7nicotinic acetylcholine receptor α7 subunitPositive5.10.1%P36544
P2RX4P2X4Positive6.61.2%Q99571
P2RX7P2X7Positive1.7%Q99572

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Muscarinic acetylcholine receptor M5, Bile acid receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, D(3) dopamine receptor, Sodium-dependent dopamine transporter, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 37 potent at pChembl ≥ 5 of 43 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ABCB17.97Kd10.6nMCHEMBL_ACT_11002226
ABCB17IC50100nMCHEMBL_ACT_11000847
ABCB17IC50100nMCHEMBL_ACT_1170231
ABCB16.7IC50200nMCHEMBL_ACT_1170228
P077276.67Ki211.8nMCHEMBL_ACT_7756973
NR1H46.58IC50260nMCHEMBL_ACT_13348761
ADORA36.54Ki289.4nMCHEMBL_ACT_7754819
P077276.43IC50374.7nMCHEMBL_ACT_7756972
P214476.3IC50500nMCHEMBL_ACT_11000875
P067956.3IC50500nMCHEMBL_ACT_11000876
ABCC16.3Ki500nMCHEMBL_ACT_11002297
P214476.3IC50500nMCHEMBL_ACT_1170229
P067956.3IC50500nMCHEMBL_ACT_1170230
ADORA36.29IC50512.1nMCHEMBL_ACT_7754818
ADRA2C6.24Ki569.7nMCHEMBL_ACT_7754833
DRD36.12Ki750.3nMCHEMBL_ACT_7756945
CHRM15.92Ki1191nMCHEMBL_ACT_7757003
CHRM35.89Ki1285nMCHEMBL_ACT_7757007
ADRA2A5.66Ki2190nMCHEMBL_ACT_7754829
DRD35.66IC502209nMCHEMBL_ACT_7756944
DRD15.65Ki2257nMCHEMBL_ACT_7756941
CHRM55.59Ki2592nMCHEMBL_ACT_7757011
SLC6A35.45Ki3540nMCHEMBL_ACT_7756949
CHRM55.44IC503608nMCHEMBL_ACT_7757010
ABCC15.42IC503800nMCHEMBL_ACT_11001421
ADRA2C5.41IC503921nMCHEMBL_ACT_7754832
SLC6A25.41Ki3915nMCHEMBL_ACT_7754841
SLC6A25.4IC503948nMCHEMBL_ACT_7754840
SLC6A35.35IC504455nMCHEMBL_ACT_7756948
DRD15.34IC504515nMCHEMBL_ACT_7756940

Target pathways

Aggregated over 3 target gene(s): CHRNA7, P2RX4, P2RX7.

Top Reactome pathways

11 total, by targets touching each:

PathwayTargetsGenes
Elevation of cytosolic Ca2+ levels2P2RX4, P2RX7
Platelet homeostasis2P2RX4, P2RX7
Purinergic signaling in leishmaniasis infection2P2RX4, P2RX7
Neurotransmitter receptors and postsynaptic signal transmission1CHRNA7
Transmission across Chemical Synapses1CHRNA7
Neuronal System1CHRNA7
Acetylcholine binding and downstream events1CHRNA7
Postsynaptic nicotinic acetylcholine receptors1CHRNA7
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors1CHRNA7
The NLRP3 inflammasome1P2RX7
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes1P2RX7

Dominant GO biological processes

GO termTargets
monoatomic ion transport3
signal transduction3
monoatomic ion transmembrane transport3
excitatory postsynaptic potential3
calcium ion transmembrane transport3
calcium ion transport2
positive regulation of MAPK cascade2
regulation of sodium ion transport2
response to ischemia2
positive regulation of calcium ion transport into cytosol2
sensory perception of pain2
calcium-mediated signaling2
positive regulation of prostaglandin secretion2
response to ATP2
response to fluid shear stress2

Indications & clinical

Indications

23 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
rosacea4MONDO:0006604EFO:1000760
onchocerciasis4MONDO:0017137EFO:0007402
strongyloidiasis4MONDO:0005974EFO:0007501
helminthiasis4MONDO:0004664EFO:1001342
lice infestation4MONDO:0003472MONDO:0003472
malaria3MONDO:0005136EFO:0001068
filarial elephantiasis3MONDO:0005761EFO:0007272
blepharitis3MONDO:0004785EFO:0009536
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
pneumonia3MONDO:0005249EFO:0003106
influenza3MONDO:0005812EFO:0007328
Dengue hemorrhagic fever2MONDO:0005358EFO:0004227
dengue disease2MONDO:0005502EFO:0005547
atopic eczema2MONDO:0004980EFO:0000274
acne2MONDO:0011438EFO:0003894
trichuriasis2MONDO:0005996EFO:0007524
ocular onchocerciasis2MONDO:0005878EFO:0007398
alcohol abuse1MONDO:0002046MONDO:0007079
triple-negative breast carcinoma1MONDO:0005494EFO:0005537
leishmaniasis0MONDO:0011989EFO:0005044

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 165.

Phase distribution

PhaseTrials
PHASE346
PHASE236
Not specified24
PHASE421
PHASE2/PHASE314
PHASE113
PHASE1/PHASE28
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07145736PHASE4RECRUITINGMoxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT01593722PHASE4COMPLETEDPost-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
NCT01903057PHASE4WITHDRAWNSafety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
NCT02616250PHASE4COMPLETEDMirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
NCT02775617PHASE4COMPLETEDAzithromycin - Ivermectin Mass Drug Administration for Skin Disease
NCT03052998PHASE4COMPLETEDIvermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
NCT03075891PHASE4COMPLETEDOracea Soolantra Association in Participants With Severe Rosacea
NCT03690453PHASE4COMPLETEDEffect of Ivermectin Metabolites on Mosquito Survival
NCT03852303PHASE4COMPLETEDIvermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
NCT04435587PHASE4UNKNOWNIvermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection
NCT04729140PHASE4UNKNOWNAn Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization
NCT04739410PHASE4COMPLETEDEffectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
NCT04746365PHASE4COMPLETEDIvermectin Role in Covid-19 Clinical Trial
NCT04779047PHASE4UNKNOWNComparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
NCT04891250PHASE4WITHDRAWNThe Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19
NCT04944082PHASE4UNKNOWNRemdesivir- Ivermectin Combination Therapy in Severe Covid-19
NCT05085665PHASE4COMPLETEDLoiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
NCT05246072PHASE4COMPLETEDEffect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients
NCT05605925PHASE4UNKNOWNIvermectin-artemisinin Combination Therapy for Eradication of Malaria
NCT05819983PHASE4COMPLETEDIvermectin/ Permethrin for Scabies
NCT06332872PHASE4UNKNOWNComparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand
NCT02735707PHASE3RECRUITINGRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT03876262PHASE3ACTIVE_NOT_RECRUITINGSafety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
NCT04351347PHASE2/PHASE3RECRUITINGThe Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
NCT00765024PHASE3COMPLETEDIvermectin Versus Albendazole for Chronic Strongyloidiasis
NCT00790998PHASE3COMPLETEDStudy Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
NCT00819520PHASE3COMPLETEDIvermectin in the Treatment of Head Lice
NCT01066585PHASE3COMPLETEDA Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
NCT01493687PHASE3COMPLETEDPhase 3 Papulopustular Rosacea Study
NCT01493947PHASE3COMPLETEDCD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
NCT01494467PHASE3COMPLETEDPhase 3 Papulopustular Rosacea Study
NCT01570504PHASE3COMPLETEDMultiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
NCT02236403PHASE3COMPLETEDTreatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%
NCT02407782PHASE3COMPLETEDOral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults
NCT02509481PHASE2/PHASE3COMPLETEDRepeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
NCT02795117PHASE3COMPLETEDComparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
NCT02841215PHASE3COMPLETEDEfficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies
NCT03074435PHASE3COMPLETEDInsecticide Resistance Management in Burkina Faso and Côte D’Ivoire
NCT03236168PHASE3COMPLETEDImpact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
NCT03238131PHASE3COMPLETEDIVM Alone vs ALB + IVM Against Onchocerciasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

42 molecules share ≥1 primary target. Top 42 by shared-target count:

MoleculeSourceStatusShared targets
SURAMINChEMBLPhase 3P2RX4, P2RX7
PAROXETINEChEMBL + PubChemPhase 4 (approved)P2RX4
ACETYLCHOLINEChEMBLPhase 4 (approved)CHRNA7
BRILLIANT BLUE GChEMBLPhase 4 (approved)P2RX7
BUPROPIONChEMBLPhase 4 (approved)CHRNA7
CARBAMOYLCHOLINEChEMBLPhase 4 (approved)CHRNA7
DULOXETINEChEMBLPhase 4 (approved)P2RX4
MECAMYLAMINEChEMBLPhase 4 (approved)CHRNA7
NALTREXONEChEMBLPhase 4 (approved)CHRNA7
NICOTINEChEMBLPhase 4 (approved)CHRNA7
TROPISETRONChEMBLPhase 4 (approved)CHRNA7
VARENICLINEChEMBLPhase 4 (approved)CHRNA7
CYTISINICLINEChEMBL + PubChemPhase 3 (approved)CHRNA7
DEXMECAMYLAMINEChEMBLPhase 3CHRNA7
ENCENICLINEChEMBLPhase 3CHRNA7
ADENOSINE TRIPHOSPHATEChEMBLPhase 2P2RX4
AZD0328ChEMBLPhase 2CHRNA7
AZD1446ChEMBLPhase 2CHRNA7
AZD9056ChEMBLPhase 2P2RX7
BRADANICLINEChEMBLPhase 2CHRNA7
CE-224535ChEMBLPhase 2P2RX7
FACINICLINEChEMBLPhase 2CHRNA7
GTS-21ChEMBLPhase 2CHRNA7
JNJ-54175446ChEMBLPhase 2P2RX7
LEVOMENOLChEMBLPhase 2CHRNA7
LOBELINEChEMBLPhase 2CHRNA7
OXATOMIDEChEMBLPhase 2P2RX7
RIVANICLINEChEMBLPhase 2CHRNA7
SSR180711ChEMBLPhase 2CHRNA7
STILONIUMChEMBLPhase 2CHRNA7
STILONIUM IODIDEChEMBLPhase 2CHRNA7
TEBANICLINEChEMBLPhase 2CHRNA7
TILORONEChEMBLPhase 2CHRNA7
ZANVIPIXANTChEMBLPhase 2P2RX7
.gamma.-aminobutyric acidPubChemApprovedCHRNA7
Berberine ChloridePubChemApprovedP2RX7
CarbamazepinePubChemApprovedP2RX4
CinacalcetPubChemApprovedCHRNA7
EslicarbazepinePubChemApprovedP2RX4
MavorixaforPubChemApprovedCHRNA7
OxcarbazepinePubChemApprovedP2RX4
SulindacPubChemApprovedCHRNA7

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot